92 results on '"Wells, Philip S"'
Search Results
2. Qualitative experiences, values, and decisional needs of patients with unprovoked venous thromboembolism who suffer bleeding—“This pill will keep you alive tonight”
3. Balancing risks of recurrent venous thromboembolism and bleeding with extended anticoagulation: a decision analysis.
4. Serial D-dimers after anticoagulant cessation in unprovoked venous thromboembolism: Data from the REVERSE cohort study
5. Thrombophilia gene mutations predict venous thromboembolism in ambulatory cancer patients receiving chemotherapy
6. Covariate-specific ROC curve analysis can accommodate differences between covariate subgroups in the evaluation of diagnostic accuracy
7. Accuracy of physicians’ intuitive risk estimation in the diagnostic management of pulmonary embolism: an individual patient data meta-analysis
8. The risk of major bleeding in patients with Factor V Leiden or Prothrombin G20210A gene mutation while on extended anticoagulant treatment for VTE
9. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis
10. Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study
11. Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial
12. VTE Prophylaxis in Critically Ill Adults
13. Executive Summary
14. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial
15. Antithrombotic Therapy for VTE Disease
16. Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis
17. Media portrayals of pulmonary embolism
18. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial
19. Long‐term risk of recurrent venous thromboembolism after a first contraceptive‐related event: Data from REVERSE cohort study
20. Risk Stratification of Pulmonary Embolism
21. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta‐analysis
22. Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding
23. Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies and outcomes from a multi-center observational study
24. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population
25. Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study
26. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
27. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial
28. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study
29. Management of direct oral anticoagulant associated bleeding: Results of a multinational survey
30. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial
31. Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study
32. Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study
33. Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE
34. N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study
35. Functional and Exercise Limitations After a First Episode of Pulmonary Embolism
36. Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores
37. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation
38. Timing of anticoagulant re-initiation following intracerebral hemorrhage in mechanical heart valves: Survey of neurosurgeons and thrombosis experts
39. A BENEFIT-RISK ANALYSIS OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WHO CONTINUED VERSUS DISCONTINUED RIVAROXABAN THERAPY AFTER AN INITIAL SIX-MONTH THERAPY
40. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials
41. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE
42. Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban
43. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study
44. Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis
45. DVT Management and Outcome Trends, 2001 to 2014
46. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort
47. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study
48. RECURRENT VENOUS THROMBOEMBOLISM IN PULMONARY EMBOLISM PATIENTS WITH RIGHT VENTRICULAR DYSFUNCTION IN THE HOKUSAI-VTE STUDY
49. Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis
50. Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.